HomeBUSINESS
BUSINESS

With Canalia Debut as Catalyst, Mitsubishi Tanabe Set to Maximize 3 Diabetes Meds
(Sep.13.2017)

Takeshi Hirokawa, General Manager for Product Marketing
Mitsubishi Tanabe Pharma is poised to take advantage of the launch earlier this month of Canalia (teneligliptin + canagliflozin), Japan’s first fixed-dose combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, to also boost sales of the two contained monodrugs ...
(LOG IN FOR FULL STORY)

News Calendar